Mutational spectrum and classification of novel mutations in patients with metastatic gastrointestinal stromal tumours

In total, ~85% of malignant gastrointestinal stromal tumours (GISTs) harbour activating mutations in one of the genes KIT or PDGFRA, while 10-15% of all GISTs have no detectable KIT or PDGFRA mutations, but could have alterations in genes of the succinate dehydrogenase complex or in BRAF, PIK3CA or...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Int J Oncol
Autores principales: Bombac, Alenka, Zakotnik, Branko, Bucic, Marina, Dragos, Vita Setrajcic, Gazic, Barbara, Stegel, Vida, Klancar, Gasper, Novakovic, Srdjan
Formato: Artigo
Lenguaje:Inglês
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7170035/
https://ncbi.nlm.nih.gov/pubmed/32236636
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ijo.2020.5028
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares